Tagged with AstraZeneca,

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction of US biotech Illumina; Bio X Cell’s new Beijing distribution centre, and the European approval of Shanghai Henlius Biotech’s extensive-stage…

China A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma; Candid Therapeutics’ T-cell engager agreement with WuXi Biologics, and the DLL3-targeted antibody parternship between Innovent Biologics and Roche. AbbVie secures…

Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…

Switzerland Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of patients in Switzerland, but the country’s status as a global biopharmaceutical R&D hub?   Major Challenges As outlined elsewhere in…

Switzerland Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational firms. Over 0.5 percent of the entire Swiss population (48,000 out of 8.8 million) work in the life sciences, 67…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster, Enhertu, among them; the launch of Novo’s Wegovy in China; Eli Lilly’s obesity partnership with Hong Kong-listed Laekna; Merck’s cancer…

China An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue decline, and Aditum Bio and Leads Biolabs’ creation of autoimmune disease-focused Oblenio Bio. AstraZeneca’s China chief in custody, believes unrelated…

China A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor Pharmaceuticals’ breast cancer portfolio; Shanghai Fosun Pharmaceutical’s African manufacturing expansion, and CanSino’s USD 17 million polio vaccine grant from the…

Switzerland Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European counterparts when it comes to healthcare digitalisation. Recent PharmaBoardroom interviewees weigh in on the country’s digital lag, its electronic patient…

Europe This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts were presented and 600 expert speakers took to the stage. The healthcare professionals and cancer drug developers in attendance were…

China A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive phase III trial results; the strategic partnership between Sino Biological and BioGeometry; CSL’s sale of its China-based plasma collection operations…

China A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese approval of AstraZeneca and Daiichi Sankyo’s gastric cancer therapy.   China’s BeiGene opens new clinical R&D and biologics manufacturing facility…